NLRP3 and Hepatic fibrosis: In a mouse model of cholestatic liver injury, MCC950 application significantly reduces the production of proinflammatory cytokines and incidence of hepatocyte death and attenuated cholestatic liver injury and liver fibrosis by inhibiting NLRP3 activation and assembly [42].